## Amendments to the Claims

- 1 40. (cancelled)
- 41. (currently amended) An isolated peptide 9, 10, or 11 amino acids in length comprising an oligopeptide selected from the group consisting of the sequence [[:]]

  KVFGSLAFV (SEQ ID NO:4233), and

  VVLGVVFGV (SEQ ID NO:4239).
- 42 44. (cancelled)
- 45. (currently amended) The <u>linked polypeptide</u> of claim <u>93</u> 41, which is <del>fused</del> linked to a T helper peptide.
- 46. (currently amended) The <u>linked poly</u>peptide of claim <u>93</u> 41, which is <del>fused</del> linked to <u>one or more</u> spacer <u>molecules</u> or <u>linker amino acids</u>.
- 47. (currently amended) The <u>linked polypeptide</u> of claim <u>93</u> 41, which is <del>fused</del> linked to a carrier.
- 48. (currently amended) The <u>linked poly</u>peptide of claim <u>93</u> 41, which is linked to a lipid.
- 49. (cancelled)
- 50. (previously presented) A homopolymer of the peptide of claim 41.
- 51. (currently amended) A heteropolymer of the The linked polypeptide of claim 93 41 and which is linked to one or more different immunogenic peptides.
- 52. (previously presented) A composition comprising the peptide of claim 41 and a carrier.

- 53. (previously presented) A composition comprising the peptide of claim 41 and a liposome.
- 54. (currently amended) A composition comprising the peptide of claim 41, and one or more different <u>immunogenic</u> peptides.
- 55 57. (cancelled)
- 58. (currently amended) The composition of claim 54, which comprises further comprising a pharmaceutically acceptable carrier.
- 59-63. (cancelled)
- 64. (currently amended) The peptide of claim 45 63, wherein the T helper peptide is a universal T helper cell epitope.
- 65. (previously presented) The peptide of claim 64, wherein the universal T helper epitope comprises the peptide aKXVWANTLKAAa (SEQ ID NO:4226), wherein "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and "a" is either D-alanine or L-alanine.
- 66-92. (cancelled)
- 93. (New) A linked polypeptide comprising a peptide consisting of the sequence KVFGSLAFV (SEQ ID NO: 4233) linked to one or more members selected from the group consisting of:
  - (a) a T helper peptide;
  - (b) one or more spacer molecules;
  - (c) a carrier;
  - (d) a lipid; and
  - (e) one or more different immunogenic peptides.

- 94. (New) A composition comprising a linked polypeptide comprising a peptide consisting of the sequence KVFGSLAFV (SEQ ID NO: 4233) linked to one or more members selected from the group consisting of:
  - (a) a T helper peptide;
  - (b) one or more spacer molecules;
  - (c) a carrier;
  - (d) a lipid; and
  - (e) one or more different immunogenic peptides.
- 95. (New) The composition of claim 94, further comprising a carrier.
- 96. (New) The composition of claim 95, further comprising a liposome.
- 97. (New) The composition of claim 94, further comprising a pharmaceutically acceptable carrier.